2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 337

Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 331

Gout Management in the Medical Community: A Claims-Based Analysis

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 33

GS-4875, a First-in-Class TPL2 Inhibitor Suppresses MEK-ERK Inflammatory Signaling and Proinflammatory Cytokine Production in Primary Human Monocytes

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 693

Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 232

Hand Digital Thermography Findings in Patients with Primary Fibromyalgia

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 247

Health Literacy, Adherence, and Quality of Life of Uveitis Patients

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 263

Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 258

Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 803

Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 165

Heterogeneity of Strategies and Methods for Assessment of Competences in Rheumatology Training: Results of a Systematic Literature Review to Inform EULAR Points to Consider

Education Poster

9:00AM-11:00AM: Abstract Number: 446

High MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) Scores in RA Patients Who Have Depression According to a Screening Questionnaire

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 597

High Prevalence of Sacroiliac Bone Marrow Edema on MRI in Post Partum Women: A Temporary Phenomenom

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 463

High-titer Rheumatoid Factor Impacts Real-life Management Outcomes of Rheumatoid Arthtitis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 91

Histonedeacetylase 1 (HDAC1): A Key Mediator of T Cells for the Pathogenesis of Rheumatoid Arthritis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 637

How Often Should SLE Patients Be Tested for Lupus Anticoagulant?

SLE – Clinical Poster I: Epidemiology & Pathogenesis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].